VAGELOS P ROY - 20 Dec 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**P. Roy Vagelos
Issuer symbol
REGN
Transactions as of
20 Dec 2022
Net transactions value
-$102,864
Form type
4
Filing time
21 Dec 2022, 16:45:22 UTC
Previous filing
20 Dec 2022
Next filing
24 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities $21,866 -30 -1.4% $728.86 2,072 20 Dec 2022 By 401(k) Plan F1
transaction REGN Common Stock Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities $80,998 -111 -5.4% $729.71 1,961 20 Dec 2022 By 401(k) Plan F2
holding REGN Common Stock 324,083 20 Dec 2022 Direct
holding REGN Common Stock 126,043 20 Dec 2022 by CLAT
holding REGN Common Stock 23,461 20 Dec 2022 by Spouse as Trustee
holding REGN Common Stock 3,609 20 Dec 2022 by trust for grandch F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 30 shares of Company stock on December 20, 2022 at prices ranging from $728.81 to $728.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2022 at each separate price.
F2 Represents volume-weighted average price of sales of 111 shares of Company stock on December 20, 2022 at prices ranging from $729.44 to $729.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2022 at each separate price.
F3 By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.